Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1101 Apheresis Allogeneic B-cell Precursor Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Slovakia 67
1102 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 72
1103 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 52
1104 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 64
1105 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Italy 68
1106 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 56
1107 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1108 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 55
1109 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1110 Apheresis Allogeneic Myelodysplastic disorder Hematology 2025 Standard Therapy France 63
1111 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
1112 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 20
1113 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 23
1114 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 73
1115 Apheresis Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 9
1116 Apheresis Allogeneic Lymphoma – DLBCL Hematology 2025 Standard Therapy United Kingdom 55
1117 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 61
1118 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Lithuania 58
1119 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 73
1120 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
1121 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2025 Standard Therapy Germany 65
1122 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1123 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 66
1124 Apheresis Autologous Diffuse large B-cell lymphoma Hematology 2025 Standard Therapy Germany 42
1125 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Netherlands 65
1126 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 60
1127 Apheresis Allogeneic Post Mielofibrosis Hematology 2025 Standard Therapy Poland 66
1128 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
1129 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 17
1130 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 72
1131 Apheresis Allogeneic T-cell prolymphocytic leukemia Hematology 2025 Standard Therapy New Zealand 64
1132 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
1133 Apheresis Allogeneic Mielofibrosis Hematology 2025 Standard Therapy Finland 68
1134 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
1135 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 34
1136 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 63
1137 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Poland 72
1138 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Switzerland 69
1139 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 52
1140 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 26
1141 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 50
1142 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Poland 71
1143 Apheresis Allogeneic Anaplastic Large Cell Lymphoma Hematology 2025 Standard Therapy Germany 3
1144 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 71
1145 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 29
1146 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 38
1147 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 28
1148 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 46
1149 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Spain 28
1150 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Slovakia 52
1151 Apheresis Allogeneic T-NHL Angioimmunoblastic T-cell Lymphoma Hematology 2025 Standard Therapy Germany 56
1152 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1153 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 23
1154 Apheresis Allogeneic Mielodysplastic syndrome Hematology 2025 Standard Therapy Spain 69
1155 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Brazil 71
1156 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 36
1157 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 58
1158 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Germany 68
1159 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 61
1160 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 35
1161 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 39
1162 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Serbia 58
1163 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 47
1164 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy Netherlands 62
1165 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 69
1166 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy United Kingdom 35
1167 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 71
1168 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 70
1169 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
1170 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 71
1171 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 39
1172 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1173 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 56
1174 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 65
1175 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Germany 65
1176 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
1177 Apheresis Autologous Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 32
1178 Apheresis Allogeneic Myelodysplastic syndrome Hematology 2025 Standard Therapy Germany 67
1179 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 56
1180 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Columbia 62
1181 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 46
1182 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 66
1183 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 46
1184 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 33
1185 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 31
1186 Apheresis Allogeneic B-Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 62
1187 Apheresis Allogeneic B-Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 62
1188 Apheresis Allogeneic Hemophagocytic lymphohistiocytosis Hematology 2025 Standard Therapy Czechia 27
1189 Apheresis Allogeneic Shwachman-Diamond Syndrome Hematology 2025 Standard Therapy Spain 11
1190 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 67
1191 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 60
1192 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy CROATIA 43
1193 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 69
1194 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Austria 61
1195 Apheresis Allogeneic Other Immune System Hematology 2025 Standard Therapy USA 62
1196 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
1197 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 63
1198 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
1199 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Denmark 50
1200 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?